Ensysce Biosciences (NASDAQ:ENSC) CEO Dr. Lynn Kirkpatrick presented at the Pain Therapeutics Summit Europe in Amsterdam on May 7-8, 2026. Her May 7 talk, “Chemical Control, Clinical Confidence: Rethinking Opioids,” described molecularly engineered opioid approaches and highlighted Ensysce platforms TAAP14 and MPAR AE aimed at reducing misuse and overdose risk. She also joined a panel on developing safer analgesics without sacrificing efficacy.
Loading…
Loading translation…
$0.3700
Last Close
Volume
Volume 223,768 is at 0.86x the 20-day average, indicating muted trading interest before this news.
normal
Technical
Price $0.37 is trading below the 200-day MA of $1.37, reflecting a longer-term downtrend.
ENSC fell 5.13% while peers were mixed: ARTL up 1.13%, PLRZ up 1.8%, SILO down 2.33%, TTNP down 3.96%, NCNA down 6.07%. Momentum scanner shows both up (ADIL, PLRZ) and down (SILO) moves, suggesting stock-specific dynamics rather than a unified sector rotation.
Date
Event
Sentiment
Move
Catalyst
Apr 16
Clinical trial progress
Positive
-4.7%
IRB approval to start final part of PF614-MPAR-102 overdose-protection study.
Apr 07
Financing tranche
Positive
+3.0%
Second $2.0M convertible preferred tranche to fund pain programs and operations.
Mar 30
Earnings and pipeline
Positive
+4.8%
FY2025 results with PF614 Phase 3 start and PF614-MPAR under Breakthrough status.
Mar 04
Investor outreach AMA
Positive
-1.0%
Live AMA discussing PF614 strategy, capital discipline, and regulatory risk.
Mar 03
Clinical publication
Positive
-15.0%
First peer-reviewed Phase 1 MPAR data showing oral overdose protection profile.
Pattern Detected
Recent history shows mixed reactions to positive updates, with 3 of 5 past news events seeing negative price moves despite constructive developments.
Recent Company History
Over the last six months, Ensysce has reported several milestones, including IRB approval for the final part of the PF614-MPAR-102 study on Apr 16, 2026 and additional financing to support pain programs on Apr 7, 2026. Full-year 2025 results on Mar 30, 2026 highlighted Phase 3 initiation for PF614 and continued PF614-MPAR progress. Investor Q&A outreach via an AMA on Mar 4, 2026 and peer-reviewed MPAR data on Mar 3, 2026 reinforced the clinical narrative. Today’s conference presentation continues that focus on TAAP and MPAR technology.
An effective S-3 shelf filed on Apr 8, 2026 registers up to 20,335,491 shares of common stock for resale by existing securityholders. The registration is for resale only, so the company does not receive proceeds from these resales, though it may receive cash if Investor Warrants are exercised. The prospectus notes 9,277,819 shares outstanding and highlights going concern language and funding only into the second quarter of 2026.
This announcement underscores Ensysce’s strategy of positioning TAAP™ and MPAR® technologies at the center of the opioid risk–benefit discussion, with the CEO highlighting chemically engineered abuse- and overdose-resistance at a key pain summit. Recent history features clinical progress, peer-reviewed data, and incremental financings, alongside an effective resale registration for 20,335,491 shares and going concern language. Investors may watch for additional clinical readouts, capital actions, and any changes in the company’s funding runway.
prodrug
medical
“PF614-MPAR, an oxycodone prodrug using MPAR® technology that limits oral overdose”
A prodrug is an inactive or less-active compound that is designed to be converted into an active drug inside the body, like a packaged meal that needs heating before it’s ready to eat. For investors, prodrugs matter because this design can improve how a medicine is absorbed, reduce side effects, extend patent protection, or enable new dosing forms — all factors that can affect a drug’s regulatory path, marketability, and commercial value.
analgesic
medical
“advancements in analgesic care, including novel therapeutic candidates in development”
An analgesic is a medication that reduces or eliminates pain without putting a person to sleep, covering common over-the-counter remedies through stronger prescription drugs. For investors, analgesics matter because their safety profile, regulatory approvals, patent protection and broad or limited use determine sales potential, liability exposure and long-term profits—think of them as either everyday household staples or specialized tools that drive revenue and risk.
central nervous system
medical
“next-generation pain and central nervous system therapeutics engineered to minimize”
The central nervous system (CNS) is the body’s main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.
plasma levels
medical
“creating a ceiling on drug plasma levels when excessive doses are taken”
Plasma levels are the concentration of a drug or biological molecule measured in the liquid portion of the blood. Investors watch these numbers because they indicate how much of a drug reaches the body, how long it stays at effective doses, and whether levels are safe; like measuring fuel in a tank to judge how far a car can go, plasma levels help predict dosing, side effects, regulatory approval chances, and commercial potential.
Breakthrough Therapy
regulatory
“PF614-MPAR, which holds FDA Breakthrough Therapy designation and has NIDA-supported”
A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.
AI-generated analysis. Not financial advice.
05/08/2026 – 08:00 AM
~ Chemical Control, Clinical Confidence: Rethinking Opioids ~
SAN DIEGO, CA / ACCESS Newswire / May 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, announced that CEO, Dr. Lynn Kirkpatrick, presented as an invited speaker and was featured on a panel at the first Pain Therapeutics Summit Europe held in Amsterdam May 7-8, 2026.
This meeting gathered experts from around the world to discuss latest advancements in analgesic care, including novel therapeutic candidates in development. Dr. Kirkpatrick’s presentation on May 7th, titled “Chemical Control, Clinical Confidence: Rethinking Opioids,” outlined a paradigm shift in opioid development-moving beyond traditional formulations to chemically engineered drugs with built-in safety controls.
Her presentation focused on redefining the opioid benefit-risk equation through molecular design, while addressing the persistent gap between analgesic efficacy and safety. Dr. Kirkpatrick highlighted Ensysce’s proprietary platforms:
TAAP™ (Trypsin-Activated Abuse Protection): A unique prodrug platform designed to improve safety and reduce non-oral routes of misuse.
MPAR® (Multi-Pill Abuse Resistance): A breakthrough technology engineered to provide overdose protection by creating a ceiling on drug plasma levels when excessive doses are taken.
“Opioids have always forced a tradeoff between efficacy and safety,” said Dr. Kirkpatrick. “Our approach is fundamentally different. By embedding control directly into the drug itself, we believe we can preserve the analgesic power physicians rely on and patients need, while actively reducing the risks that have defined this class for decades.”
In addition to her presentation, Dr. Kirkpatrick participated in a panel of leading experts in the analgesic space to discuss “Safer Analgesics Without Losing Efficacy”. The panel discussed key developments in the field that may lead to more effective pain products with better safety profiles. During the session, Dr. Kirkpatrick and the other experts discussed their clinical programs more fully and answered additional questions from the audience.
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may,” “intends,” “can,” “might,” “will,” “expect,” “plan,” “possible,” “believe” and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce’s management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce’s business is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce’s product candidates; the availability or commercial potential of product candidates; continuation of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce’s and its partners’ ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce’s most recent annual report on Form 10-K and current reports on Form 8-K, available free of charge at the SEC’s website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences
View the original press release on ACCESS Newswire
FAQ
What did Ensysce (ENSC) CEO present at the Pain Therapeutics Summit Europe on May 7, 2026?
Dr. Lynn Kirkpatrick presented on chemically engineered opioids with built-in safety controls, focusing on TAAP14 and MPAR AE. According to the company, the talk framed a paradigm shift toward prodrug and abuse-resistant designs intended to separate analgesic efficacy from overdose risk.
What are TAAP14 and MPAR AE described by Ensysce (ENSC) at the Amsterdam symposium?
TAAP14 is a trypsin-activated prodrug platform; MPAR AE is a multi-pill abuse resistance technology. According to the company, TAAP14 targets non-oral misuse reduction and MPAR AE aims to limit plasma levels if excessive doses are taken.
When and where did Ensysce (ENSC) discuss its clinical pain programs in 2026?
Ensysce discussed its programs at the Pain Therapeutics Summit Europe in Amsterdam on May 7-8, 2026. According to the company, the CEO and panelists reviewed clinical development approaches and answered audience questions about safer analgesic candidates.
How did Ensysce (ENSC) describe the goal of its opioid design strategy?
The company described embedding safety controls into molecule design to preserve analgesia while reducing misuse and overdose potential. According to the company, this strategy focuses on molecular features and delivery characteristics that alter abuse and overdose pharmacology.
Did Ensysce (ENSC) participate in panel discussions at the Pain Therapeutics Summit Europe?
Yes. Dr. Lynn Kirkpatrick served on a panel titled “Safer Analgesics Without Losing Efficacy.” According to the company, the panel exchanged updates on clinical programs and debated how to improve safety profiles without sacrificing therapeutic benefit.
What investor-relevant details did Ensysce (ENSC) provide at the Amsterdam meeting?
The company highlighted its proprietary platforms TAAP14 and MPAR AE and their intended safety mechanisms. According to the company, presenters discussed how these technologies could influence clinical development pathways for opioid therapeutics.